ELV vs HUM
Elevance Health, Inc. and Humana Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ELV | HUM |
|---|---|---|
| Revenue | $199.1B | $129.7B |
| Net income | $5.7B | $1.2B |
| Gross margin | 89.4% | — |
| Net margin | 2.8% | 0.9% |
| Return on equity | 13.3% | 7.0% |
| Diluted EPS | $25.21 | $9.84 |
| Dividend / share | — | $3.54 |
| Payout ratio | 27.0% | 36.2% |
| Free cash flow | $3.2B | $375.0M |
| Equity | $43.9B | $17.7B |
| Net debt / equity | 0.51× | 0.46× |
| Current ratio | 1.54× | 2.00× |
| Revenue CAGR 5y | 10.3% | 10.9% |
| Profit CAGR 5y | 4.4% | −18.8% |
ELV bills 1.5× the revenue of HUM, and keeps more of each dollar of revenue as profit (2.8% against 0.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
10 years side by side
| Fiscal year | ELV | HUM |
|---|---|---|
| FY2025 | $199.1B | $129.7B |
| FY2024 | $177.0B | $117.8B |
| FY2023 | $171.3B | $106.4B |
| FY2022 | $156.6B | $92.9B |
| FY2021 | $138.6B | $83.1B |
| FY2020 | $121.9B | $77.2B |
| FY2019 | $104.2B | $64.9B |
| FY2018 | $92.1B | $56.9B |
| FY2017 | $90.0B | $53.8B |
| FY2016 | $84.9B | $54.4B |
Net income by year
Bottom line
| Fiscal year | ELV | HUM |
|---|---|---|
| FY2025 | $5.7B | $1.2B |
| FY2024 | $6.0B | $1.2B |
| FY2023 | $6.0B | $2.5B |
| FY2022 | $5.9B | $2.8B |
| FY2021 | $6.2B | $2.9B |
| FY2020 | $4.6B | $3.4B |
| FY2019 | $4.8B | $2.7B |
| FY2018 | $3.8B | $1.7B |
| FY2017 | $3.8B | $2.4B |
| FY2016 | $2.5B | $614.0M |